William Blair analyst Myles Minter has reiterated their bullish stance on IONS stock, giving a Buy rating on April 23.
Myles Minter has given his Buy rating due to a combination of factors including Ionis Pharmaceuticals’ strong first-quarter performance and promising future outlook. The company reported total revenue of $132 million, surpassing both Myles’ estimate and consensus expectations, largely driven by the successful early launch of Tryngolza which exceeded initial revenue projections.
Additionally, Ionis has updated its 2025 guidance, reflecting increased revenue expectations and a narrower non-GAAP operating loss. The company anticipates ending the year with a substantial cash reserve, bolstered by successful licensing transactions. These factors, alongside stable R&D expenses and a strategic increase in operating expenses to support product launches, contribute to Myles Minter’s positive outlook on Ionis Pharmaceuticals.
In another report released on April 23, TD Cowen also maintained a Buy rating on the stock with a $59.00 price target.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IONS in relation to earlier this year.